When ubiquitin meets NF-κB: A trove for anti-cancer drug development

Current Pharmaceutical Design

Volumn 19, Issue 18, 2013, Pages 3263-3275

  Wu, Zhao Hui ^a   Shi, Yuling ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Cancer; NF B; Therapeutics; Ubiquitin

Indexed keywords

ANTINEOPLASTIC AGENT; AT 406; BIRINAPANT; BORTEZOMIB; CARFILZOMIB; DELANZOMIB; GDC 0152; GDC 0917; HGS 1029; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; IXAZOMIB CITRATE; LCL 161; MLN 9074; MYELOID DIFFERENTIATION FACTOR 88; ONY 0912; OPROZOMIB; PEVONEDISTAT; PHOSPHOTRANSFERASE; PROTEASOME; RG 7112; SALINOSPORAMIDE A; SERDEMETAN; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BREAST CANCER; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; DNA DAMAGE; DNA MODIFICATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ANALYSIS; EPIGENETICS; FOOD AND DRUG ADMINISTRATION; GENE TARGETING; GENETIC TRANSCRIPTION; GENOTOXICITY; GLIOBLASTOMA; HISTONE UBIQUITINATION; HUMAN; INNATE IMMUNITY; INTERFERON PRODUCTION; KIDNEY CANCER; LARGE CELL LYMPHOMA; LEUKEMIA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MANTLE CELL LYMPHOMA; METASTASIS; MULTIPLE MYELOMA; NEDDYLATION; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; SOLID TUMOR; TRANSCRIPTION REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DRUG DESIGN; HUMANS; NEOPLASMS; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PYRAZINES; SIGNAL TRANSDUCTION; UBIQUITIN; UBIQUITINATION;

EID: 84878875514     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319180010     Document Type: Article

References (164)

1. Hershko A, Ciechanover A, Rose IA. Resolution of the ATP-dependent proteolytic system from reticulocytes: a component that interacts with ATP. Proc Natl Acad Sci USA 1979; 76: 3107-10.
2. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986; 46: 705-16.
3. Pickart CM, Cohen RE. Proteasomes and their kin: proteases in the machine age. Nat Rev Mol Cell Biol 2004; 5: 177-87.
4. Ciechanover A. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 2005; 6: 79-87.
5. Chen ZJ, Sun LJ. Nonproteolytic Functions of Ubiquitin in Cell Signaling. Mol Cell 2009; 33: 275-286.
6. Bedford L, Lowe J, Dick LR, Mayer RJ, Brownell JE. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov 2011; 10: 29-46.
7. Hayden MS, Ghosh S. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 2012; 26: 203-34.
8. Ruschak AM, Slassi M, Kay LE, Schimmer AD. Novel proteasome inhibitors to overcome bortezomib resistance. J Natl Cancer Inst 2011; 103: 1007-17.
9. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008; 132: 344-62.
10. Chen ZJ. Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol 2005; 7: 758-65.
11. Skaug B, Jiang X, Chen ZJ. The Role of Ubiquitin in NF-kB Regulatory Pathways. Annu Rev Biochem 2009; 78: 769-96.
12. Kulathu Y, Komander D. Atypical ubiquitylation - the unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages. Nat Rev Mol Cell Biol 2012; 13: 508-23.
13. Iwai K. Diverse ubiquitin signaling in NF-κB activation. Trends cell biol 2012; 22: 355-64.
14. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67: 425-79.
15. Goldstein G, Scheid M, Hammerling U, Schlesinger DH, Niall HD, Boyse EA. Isolation of a polypeptide that has lymphocyte-differentiating properties and is probably represented universally in living cells. Proc Natl Acad Sci USA 1975; 72: 11-5.
16. Ciechanover A, Hod Y, Hershko A. A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes. Biochem Biophys Res Commun 1978; 81: 1100-5.
17. Bloom J, Amador V, Bartolini F, DeMartino G, Pagano M. Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation. Cell 2003; 115: 71-82.
18. Ciechanover A, Ben-Saadon R. N-terminal ubiquitination: more protein substrates join in. Trends in cell biology 2004; 14: 103-6.
19. Kirisako T, Kamei K, Murata S, et al. A ubiquitin ligase complex assembles linear polyubiquitin chains. EMBO J 2006; 25: 4877-87.
20. Iwai K, Tokunaga F. Linear polyubiquitination: a new regulator of NF-[kappa]B activation. EMBO Rep 2009; 10: 706-13.
21. Liu YC. Ubiquitin ligases and the immune response. Annu Rev Immuno 2004; 22: 81-127.
22. Lipkowitz S, Weissman AM. RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat Rev Cancer 2011; 11: 629-43.
23. Eisenhaber B, Chumak N, Eisenhaber F, Hauser MT. The ring between ring fingers (RBR) protein family. Genome Biol 2007; 8: 209.
24. Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and [beta]-TrCP: tipping the scales of cancer. Nat Rev Cancer 2008; 8: 438-49.
25. Nijman SMB, Luna-Vargas MPA, Velds A, et al. A Genomic and Functional Inventory of Deubiquitinating Enzymes. Cell 2005; 123: 773-86.
26. Komander D, Clague MJ, Urbe S. Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 2009; 10: 550-63.
27. Sowa ME, Bennett EJ, Gygi SP, Harper JW. Defining the Human Deubiquitinating Enzyme Interaction Landscape. Cell 2009; 138: 389-403.
28. Hammond-Martel I, Yu H, Affar EB. Roles of ubiquitin signaling in transcription regulation. Cell Signal 2012; 24: 410-21.
29. Moldovan G-L, Pfander B, Jentsch S. PCNA, the Maestro of the Replication Fork. Cell 2007; 129: 665-79.
30. Bergink S, Jentsch S. Principles of ubiquitin and SUMO modifications in DNA repair. Nature 2009; 458: 461-7.
31. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W. Mono-versus polyubiquitination: differential control of p53 fate by Mdm2. Science 2003; 302: 1972-5.
32. Hicke L, Dunn R. Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annu Rev Cell Dev Biol 2003; 19: 141-72.
33. Varadan R, Walker O, Pickart C, Fushman D. Structural Properties of Polyubiquitin Chains in Solution. J Mol Biol 2002; 324: 637-47.
34. Thrower JS, Hoffman L, Rechsteiner M, Pickart CM. Recognition of the polyubiquitin proteolytic signal. EMBO J 2000; 19: 94-102.
35. Behrends C, Harper JW. Constructing and decoding unconventional ubiquitin chains. Nat Struct Mol Biol 2011; 18: 520-8.
36. Dynek JN, Goncharov T, Dueber EC, et al. c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. EMBO J 2010; 29: 4198-209.
37. Ikeda F, Dikic I. Atypical ubiquitin chains: new molecular signals. EMBO Rep 2008; 9: 536-42.
38. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225-60.
39. Perkins ND, Gilmore TD. Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ 2006; 13: 759-72.
40. Vallabhapurapu S, Karin M. Regulation and Function of NF-kappaB Transcription Factors in the Immune System. Annu Rev Immuno 2009; 27: 693-733.
41. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004; 18: 2195-224.
42. McCool KW, Miyamoto S. DNA damage-dependent NF-kappaB activation: NEMO turns nuclear signaling inside out. Immunol Rev 2012; 246: 311-26.
43. Wu ZH, Miyamoto S. Many faces of NF-kappaB signaling induced by genotoxic stress. J Mol Med 2007; 85: 1187-1202.
44. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitinproteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell 1994; 78: 773-85.
45. Yaron A, Hatzubai A, Davis M, et al. Identification of the receptor component of the IkappaBalpha-ubiquitin ligase. Nature 1998; 396: 590-4.
46. Alkalay I, Yaron A, Hatzubai A, Orian A, Ciechanover A, Ben-Neriah Y. Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. Proceedings of the National Academy of Sciences 1995; 92: 10599-603.
47. Chen Z, Hagler J, Palombella VJ, et al. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev 1995; 9: 1586-97.
48. Cohen S, Achbert-Weiner H, Ciechanover A. Dual effects of IkappaB kinase beta-mediated phosphorylation on p105 Fate: SCF(beta-TrCP)-dependent degradation and SCF(beta-TrCP)-independent processing. Mol Cell Biol 2004; 24: 475-86.
49. Moorthy AK, Savinova OV, Ho JQ, Wang VY, Vu D, Ghosh G. The 20S proteasome processes NF-kappaB1 p105 into p50 in a translation-independent manner. EMBO J 2006; 25: 1945-56.
50. Maine GN, Mao X, Komarck CM, Burstein E. COMMD1 promotes the ubiquitination of NF-[kappa]B subunits through a cullin-containing ubiquitin ligase. EMBO J 2007; 26: 436-47.
51. Ryo A, Suizu F, Yoshida Y, et al. Regulation of NF-κB Signaling by Pin1-Dependent Prolyl Isomerization and Ubiquitin-Mediated Proteolysis of p65/RelA. Mol Cell 2003; 12: 1413-26.
52. Tanaka T, Grusby MJ, Kaisho T. PDLIM2-mediated termination of transcription factor NF-[kappa]B activation by intranuclear sequestration and degradation of the p65 subunit. Nat Immunol 2007; 8: 584-91.
53. Carmody RJ, Ruan Q, Palmer S, Hilliard B, Chen YH. Negative Regulation of Toll-Like Receptor Signaling by NF-{kappa}B p50 Ubiquitination Blockade. In: ed.^eds., Science 2007; pp. 675-8.
54. Chen ZJ, Parent L, Maniatis T. Site-specific phosphorylation of IkappaBalpha by a novel ubiquitination-dependent protein kinase activity. Cell 1996; 84: 853-62.
55. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science 2002; 296: 1634-5.
56. Yin Q, Lamothe B, Darnay BG, Wu H. Structural Basis for the Lack of E2 Interaction in the RING Domain of TRAF2. Biochemistry 2009; 48: 10558-67.
57. Alvarez SE, Harikumar KB, Hait NC, et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature 2010; 465: 1084-1088.
58. Ea CK, Deng L, Xia ZP, Pineda G, Chen ZJ. Activation of IKK by TNF[alpha] Requires Site-Specific Ubiquitination of RIP1 and Polyubiquitin Binding by NEMO. Mol Cell 2006; 22: 245-57.
59. Wu CJ, Conze DB, Li T, Srinivasula SM, Ashwell JD. Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-kappaB activation. Nat Cell Biol 2006; 8: 398-406.
60. Kanayama A, Seth RB, Sun L, et al. TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol Cell 2004; 15: 535-48.
61. Lo YC, Lin SC, Rospigliosi CC, et al. Structural basis for recognition of diubiquitins by NEMO. Mol Cell 2009; 33: 602-15.
62. Tang ED, Wang CY, Xiong Y, Guan KL. A Role for NF-kB Essential Modifier/IkB Kinase-gamma (NEMO/IKKgamma) Ubiquitination in the Activation of the IkB Kinase Complex by Tumor Necrosis Factor-a. J Biol Chem 2003; 278: 37297-305.
63. Tokunaga F, Sakata S, Saeki Y, et al. Involvement of linear polyubiquitylation of NEMO in NF-kappaB activation. Nat Cell Biol 2009; 11: 123-32.
64. Harhaj EW, Dixit VM. Regulation of NF-kappaB by deubi-quitinases. Immunol Rev 2012; 246: 107-24.
65. Komander D, Lord CJ, Scheel H, et al. The Structure of the CYLD USP Domain Explains Its Specificity for Lys63-Linked Poly-ubiquitin and Reveals a B Box Module. Mol Cell 2008; 29: 451-64.
66. Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G. The tumour suppressor CYLD negatively regulates NF-[kappa]B signalling by deubiquitination. Nature 2003; 424: 801-5.
67. Wertz IE, O'Rourke KM, Zhou H, et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004; 430: 694-9.
68. Skaug B, Chen J, Du F, He J, Ma A, Chen Zhijian J. Direct, Noncatalytic Mechanism of IKK Inhibition by A20. Mol Cell 2011; 44: 559-71.
69. Xia ZP, Sun L, Chen X, et al. Direct activation of protein kinases by unanchored polyubiquitin chains. Nature 2009; 461: 114-9.
70. Zeng W, Sun L, Jiang X, et al. Reconstitution of the RIG-I pathway reveals a signaling role of unanchored polyubiquitin chains in innate immunity. Cell 2010; 141: 315-30.
71. Xu M, Skaug B, Zeng W, Chen ZJ. A ubiquitin replacement strategy in human cells reveals distinct mechanisms of IKK activation by TNFalpha and IL-1beta. Mol Cell 2009; 36: 302-14.
72. Gerlach B, Cordier SM, Schmukle AC, et al. Linear ubiquitination prevents inflammation and regulates immune signalling. Nature 2011; 471: 591-6.
73. Kawai T, Akira S. Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and Immunity. Immunity 2011; 34: 637-50.
74. Chang M, Jin W, Sun S-C. Peli1 facilitates TRIF-dependent Toll-like receptor signaling and proinflammatory cytokine production. Nat Immunol 2009; 10: 1089-95.
75. Tseng P-H, Matsuzawa A, Zhang W, Mino T, Vignali DAA, Karin M. Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. Nat Immunol 2010; 11: 70-5.
76. Lee K-Y, D'Acquisto F, Hayden MS, Shim J-H, Ghosh S. PDK1 Nucleates T Cell Receptor-Induced Signaling Complex for NF-κB Activation. Science 2005; 308: 114-8.
77. Wang D, You Y, Case SM, et al. A requirement for CARMA1 in TCR-induced NF-kappa B activation. Nature immunology 2002; 3: 830-5.
78. Sun L, Deng L, Ea CK, Xia ZP, Chen ZJ. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol Cell 2004; 14: 289-301.
79. Chen ZJ. Ubiquitination in signaling to and activation of IKK. Immunol Rev 2012; 246: 95-106.
80. Paul S, Kashyap Anuj K, Jia W, He YW, Schaefer Brian C. Selective Autophagy of the Adaptor Protein Bcl10 Modulates T Cell Receptor Activation of NF-κB. Immunity 2012; 36: 947-58.
81. Scharschmidt E, Wegener E, Heissmeyer V, Rao A, Krappmann D. Degradation of Bcl10 Induced by T-Cell Activation Negatively Regulates NF-κB Signaling. Mol Cell Biol 2004; 24: 3860-73.
82. Hadian K, Krappmann D. Signals from the Nucleus: Activation of NF-{kappa}B by Cytosolic ATM in the DNA Damage Response. Sci. Signal. 2011; 4: pe2.
83. Miyamoto S. Nuclear initiated NF-[kappa]B signaling: NEMO and ATM take center stage. Cell Res 2011; 21: 116-30.
84. Huang TT, Wuerzberger-Davis SM, Wu ZH, Miyamoto S. Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress. Cell 2003; 115: 565-76.
85. Mabb AM, Wuerzberger-Davis SM, Miyamoto S. PIASy mediates NEMO sumoylation and NF-kappaB activation in response to genotoxic stress. Nat Cell Biol 2006; 8: 986-93.
86. Janssens S, Tinel A, Lippens S, Tschopp J. PIDD mediates NF-kappaB activation in response to DNA damage. Cell 2005; 123: 1079-92.
87. Stilmann M, Hinz M, Arslan SC, Zimmer A, Schreiber V, Scheidereit C. A Nuclear Poly(ADP-Ribose)-Dependent Signalosome Confers DNA Damage-Induced IkB Kinase Activation. Mol Cell 2009; 36: 365-78.
88. Wu ZH, Shi Y, Tibbetts RS, Miyamoto S. Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli. Science 2006; 311: 1141-6.
89. Wu ZH, Wong ET, Shi Y, et al. ATM-and NEMO-Dependent ELKS Ubiquitination Coordinates TAK1-Mediated IKK Activation in response to Genotoxic Stress. Mol Cell 2010; 40: 75-86.
90. Hinz M, Stilmann M, Arslan SC, Khanna KK, Dittmar G, Scheidereit C. A Cytoplasmic ATM-TRAF6-cIAP1 Module Links Nuclear DNA Damage Signaling to Ubiquitin-Mediated NF-kappaB Activation. Mol Cell 2010; 40: 63-74.
91. Komander D, Reyes-Turcu F, Licchesi JDF, Odenwaelder P, Wilkinson KD, Barford D. Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains. EMBO Rep 2009; 10: 466-73.
92. Ikeda F, Deribe YL, Skanland SS, et al. SHARPIN forms a linear ubiquitin ligase complex regulating NF-[kgr]B activity and apoptosis. Nature 2011; 471: 637-41.
93. Tokunaga F, Nakagawa T, Nakahara M, et al. SHARPIN is a component of the NF-kB-activating linear ubiquitin chain assembly complex. Nature 2011; 471: 633-6.
94. Schmukle AC, Walczak H. No one can whistle a symphony alone-how different ubiquitin linkages cooperate to orchestrate NF-kappaB activity. J Cell Sci 2012; 125: 549-59.
95. Nakamura M, Tokunaga F, Sakata S-I, Iwai K. Mutual regulation of conventional protein kinase C and a ubiquitin ligase complex. Biochem Biophys Res Commun 2006; 351: 340-7.
96. Inn KS, Gack MU, Tokunaga F, et al. Linear Ubiquitin Assembly Complex Negatively Regulates RIG-I-and TRIM25-Mediated Type I Interferon Induction. Mol Cell 2011; 41: 354-65.
97. Haas TL, Emmerich CH, Gerlach B, et al. Recruitment of the Linear Ubiquitin Chain Assembly Complex Stabilizes the TNF-R1 Signaling Complex and is Required for TNF-Mediated Gene Induction. Mol Cell 2009; 36: 831-44.
98. Rahighi S, Ikeda F, Kawasaki M, et al. Specific recognition of linear ubiquitin chains by NEMO is important for NF-kappaB activation. Cell 2009; 136: 1098-109.
99. Niu J, Shi Y, Iwai K, Wu Z-H. LUBAC regulates NF-[kappa]B activation upon genotoxic stress by promoting linear ubiquitination of NEMO. EMBO J 2011; 30: 3741-53.
100. Yan N, Chen ZJ. Intrinsic antiviral immunity. Nat Immunol 2012; 13: 214-222.
101. Gack MU, Shin YC, Joo CH, et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 2007; 446: 916-20.
102. Carter RS, Pennington KN, Ungurait BJ, Arrate P, Ballard DW. Signal-induced Ubiquitination of I B Kinase-. J Biol Chem 2003; 278: 48903-6.
103. Carter RS, Pennington KN, Arrate P, Oltz EM, Ballard DW. Site-specific Monoubiquitination of I B Kinase IKK Regulates Its Phosphorylation and Persistent Activation. J Biol Chem 2005; 280: 43272-9.
104. Hochrainer K, Racchumi G, Zhang S, Iadecola C, Anrather J. Monoubiquitination of nuclear RelA negatively regulates NF-kappaB activity independent of proteasomal degradation. Cell Mol Life Sci 2012; 69: 2057-73.
105. Jin L, Williamson A, Banerjee S, Philipp I, Rape M. Mechanism of Ubiquitin-Chain Formation by the Human Anaphase-Promoting Complex. Cell 2008; 133: 653-65.
106. Xu P, Duong DM, Seyfried NT, et al. Quantitative Proteomics Reveals the Function of Unconventional Ubiquitin Chains in Proteasomal Degradation. Cell 2009; 137: 133-45.
107. Huang H, Jeon MS, Liao L, et al. K33-Linked Polyubiquitination of T Cell Receptor-Regulates Proteolysis-Independent T Cell Signaling. Immunity 2010; 33: 60-70.
108. Arimoto K-I, Funami K, Saeki Y, et al. Polyubiquitin conjugation to NEMO by triparite motif protein 23 (TRIM23) is critical in antiviral defense. Proc Natl Acad Sci USA 2010; 107: 15856-61.
109. Kim HJ, Hawke N, Baldwin AS. NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ 2006; 13: 738-47.
110. Perkins ND. The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer 2012; 12: 121-32.
111. Braun T, Carvalho G, Fabre C, Grosjean J, Fenaux P, Kroemer G. Targeting NF-kappaB in hematologic malignancies. Cell Death Differ 2006; 13: 748-58.
112. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749-59.
113. Karin M, Lawrence T, Nizet V. Innate Immunity Gone Awry: Linking Microbial Infections to Chronic Inflammation and Cancer. Cell 2006; 124: 823-35.
114. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001; 107: 241-6.
115. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5: 297-309.
116. Hanahan D, Weinberg Robert A. Hallmarks of Cancer: The Next Generation. Cell 2011; 144: 646-74.
117. Baud V, Karin M. Is NF-[kappa]B a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009; 8: 33-40.
118. Luo J, Solimini NL, Elledge SJ. Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction. Cell 2009; 136: 823-37.
119. Skaar JR, Pagano M. Control of cell growth by the SCF and APC/C ubiquitin ligases. Curr Opin Cell Biol 2009; 21: 816-24.
120. Huen MS, Sy SM, Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol 2010; 11: 138-48.
121. Moldovan GL, D'Andrea AD. How the fanconi anemia pathway guards the genome. Annu Rev Genet 2009; 43: 223-49.
122. Lee JT, Gu W. The multiple levels of regulation by p53 ubiquitination. Cell Death Differ 2010; 17: 86-92.
123. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat genet 1994; 7: 85-90.
124. Duan S, Cermak L, Pagan JK, et al. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature 2012; 481: 90-3.
125. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004; 5: 417-21.
126. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 2006; 57: 33-47.
127. Markovina S, Callander NS, O'Connor SL, et al. Bortezomib-Resistant Nuclear Factor-B Activity in Multiple Myeloma Cells. Mol Cancer Res 2008; 6: 1356-64.
128. Hideshima T, Ikeda H, Chauhan D, et al. Bortezomib induces canonical nuclear factor-B activation in multiple myeloma cells. Blood 2009; 114: 1046-52.
129. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003; 101: 1530-4.
130. Yang Y, Ikezoe T, Saito T, Kobayashi M, Koeffler HP, Taguchi H. Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer sci 2004; 95: 176-80.
131. Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007; 67: 6383-91.
132. Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007; 110: 3281-90.
133. Soucy TA, Smith PG, Milhollen MA, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009; 458: 732-6.
134. Watson IR, Irwin MS, Ohh M. NEDD8 Pathways in Cancer, Sine Quibus Non. Cancer Cell 2011; 19: 168-76.
135. Schulman BA, Wade Harper J. Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways. Nat Rev Mol Cell Biol 2009; 10: 319-31.
136. Duda DM, Borg LA, Scott DC, Hunt HW, Hammel M, Schulman BA. Structural Insights into NEDD8 Activation of Cullin-RING Ligases: Conformational Control of Conjugation. Cell 2008; 134: 995-1006.
137. Yamoah K, Oashi T, Sarikas A, Gazdoiu S, Osman R, Pan ZQ. Autoinhibitory regulation of SCF-mediated ubiquitination by human cullin 1's C-terminal tail. Proc Natl Acad Sci USA 2008; 105: 12230-5.
138. Brownell JE, Sintchak MD, Gavin JM, et al. Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ. Mol Cell 2010; 37: 102-11.
139. Swords RT, Kelly KR, Smith PG, et al. Inhibition of NEDD8-activating enzyme: A novel approach for the treatment of acute myeloid leukemia. Blood 2010; 115: 3796-800.
140. Milhollen MA, Traore T, Adams-Duffy J, et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB-dependent lymphoma. Blood 2010; 116: 1515-23.
141. Mackintosh C, Garcia-Dominguez DJ, Ordonez JL, et al. WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells. Oncogene 2012.
142. Luo Z, Yu G, Lee HW, et al. The Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth. Cancer Res 2012; 72: 3360-71.
143. Wei D, Li H, Yu J, et al. Radiosensitization of Human Pancreatic Cancer Cells by MLN4924, an Investigational NEDD8-Activating Enzyme Inhibitor. Cancer Res 2012; 72: 282-93.
144. Milhollen Michael A, Thomas Michael P, Narayanan U, et al. Treatment-Emergent Mutations in NAE Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924. Cancer Cell 2012; 21: 388-401.
145. Yang Y, Kitagaki J, Dai RM, et al. Inhibitors of Ubiquitin-Activating Enzyme (E1), a New Class of Potential Cancer Therapeutics. Cancer Res 2007; 67: 9472-81.
146. Xu GW, Ali M, Wood TE, et al. The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood 2010; 115: 2251-9.
147. Kitagaki J, Yang Y, Saavedra JE, Colburn NH, Keefer LK, Perantoni AO. Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53. Oncogene 2008; 28: 619-24.
148. Pulvino M, Liang Y, Oleksyn D, et al. Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A. Blood 2012.
149. Wang Q, Moyret-Lalle C, Couzon F, et al. Alterations of anaphase-promoting complex genes in human colon cancer cells. Oncogene 2003; 22: 1486-90.
150. Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 2012; 12: 68-78.
151. Marine JC, Lozano G. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ 2009; 17: 93-102.
152. Issaeva N, Bozko P, Enge M, et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004; 10: 1321-8.
153. Vassilev LT, Vu BT, Graves B, et al. In vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2. Science 2004; 303: 844-8.
154. Terzian T, Suh YA, Iwakuma T, et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 2008; 22: 1337-44.
155. Wu H, Tschopp J, Lin SC. Smac Mimetics and TNF: A Dangerous Liaison? Cell 2007; 131: 655-8.
156. Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 2012; 11: 109-24.
157. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG. A Small Molecule Smac Mimic Potentiates TRAIL-and TNF-Mediated Cell Death. Science 2004; 305: 1471-4.
158. Vince JE, Wong WWL, Khan N, et al. IAP Antagonists Target cIAP1 to Induce TNF-Dependent Apoptosis. Cell 2007; 131: 682-93.
159. Varfolomeev E, Blankenship JW, Wayson SM, et al. IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNF-Dependent Apoptosis. Cell 2007; 131: 669-81.
160. Petersen SL, Wang L, Yalcin-Chin A, et al. Autocrine TNF Signaling Renders Human Cancer Cells Susceptible to Smac-Mimetic-Induced Apoptosis. Cancer Cell 2007; 12: 445-56.
161. Feltham R, Bettjeman B, Budhidarmo R, et al. Smac Mimetics Activate the E3 Ligase Activity of cIAP1 Protein by Promoting RING Domain Dimerization. J Biol Chem 2011; 286: 17015-28.
162. Dammer EB, Na CH, Xu P, et al. Polyubiquitin Linkage Profiles in Three Models of Proteolytic Stress Suggest the Etiology of Alzheimer Disease. J Biol Chem 2011; 286: 10457-65.
163. Enzler T, Sano Y, Choo MK, et al. Cell-Selective Inhibition of NF-κB Signaling Improves Therapeutic Index in a Melanoma Chemotherapy Model. Cancer Discovery 2011; 1: 496-507.
164. Vijay-Kumar S, Bugg CE, Cook WJ. Structure of ubiquitin refined at 1.8Åresolution. J Mol Biol 1987; 194: 531-44.